Sexually Transmitted Disease Surveillance 1995
Division of STD Prevention September 1996 U.S. Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention Division of STD Prevention Atlanta, Georgia 30333 Copyright Information All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated. Suggested Citation Division of STD Prevention. Sexually Transmitted Disease Surveillance, 1995. U.S. Department of Health and Human Services, Public Health Service. Atlanta: Centers for Disease Control and Prevention, September 1996. Copies can be obtained from Information Technology and Services Office, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-06, Atlanta, Georgia 30333 or by telephone at (404) 639-1819. The reports for 1993 through 1995 are now available electronically on CDC WONDER. For information about registering for CDC WONDER, please contact CDC's Information Resource Management Office at (404) 332-4569. These reports are also available from the Internet via the CDC home page address http://www.cdc.gov. STDs in the South Public Health Impact The southern region (Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, Oklahoma, North Carolina, South Carolina, Tennessee, Texas, Virginia, West Virginia) has had higher rates of primary and secondary (P&S) syphilis and gonorrhea than other regions of the country. The reasons for regional differences in rates are not well understood, but may include differences in racial and ethnic distribution of the population, poverty, and availability and quality of health care services. These racial and ethnic differentials in STD rates are particularly disturbing in light of the fact that STDs facilitate HIV transmission at least two to five fold. High HIV prevalence among childbearing women living in the South may be due, in part, to the high rates of these others STDs. Data from a randomized controlled trial of STD treatment to prevent HIV infection suggest that as much as a 40% reduction in HIV incidence might be achieved in areas with high STD rates (1). Observations -- The South has consistently had higher rates of both gonorrhea and P&S syphilis compared with other regions throughout the 1980's and 1990's (Figure_7, Figure_8, Figure_19, and Figure_21, Table_11 and Table_23). -- In 1995, the 10 states with the highest rates of gonorrhea were all located in the South (Figure_7 and Table_10). Thirteen of the 17 states with rates of P&S syphilis above the revised HP2000 objective of 4 per 100,000 population were located in the South (Figure_19 and Figure_20; Table_22). All 8 states with rates of P&S syphilis that exceeded 12 cases per 100,000 population (or three times the revised HP2000 national objective) were located in the South (Figure_19 and Table_22). -- In 1995, 492 (84%) of 588 counties with P&S syphilis rates above the revised HP2000 objective were located in the South (Figure_20 and Figure_N). -- Between 1994 and 1995, P&S syphilis rates increased in 244 (54%) of 449 counties in the South that had 1995 rates greater than 4 cases per 100,000 population (Figure_O). -- Rates of P&S syphilis in African-Americans by region show that rates in this group, while decreasing, are high regardless of region (Figure_P). Figure_N. South -- Primary and secondary syphilis case rates by county, 1995 Figure_O. South -- Increases and decreases in cases of primary and secondary syphilis in 1995 compared with 1994 cases, by county Figure_P. Primary and secondary syphilis -- Rates in African-Americans by region: 1981-1995 --------------- (1) Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, ka-Gina G, Newell J, Mugeye K, Mabey D, Hayes R. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995;346:530-6.
This page last reviewed: Monday, February 01, 2016
This information is provided as technical reference material. Please contact us at cwus@cdc.gov to request a simple text version of this document.